{"id":942704,"date":"2026-03-06T16:04:38","date_gmt":"2026-03-06T21:04:38","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/contact-the-gross-law-firm-by-april-6-2026-deadline-to-join-class-action-against-ultragenyx-pharmaceutical-inc-rare\/"},"modified":"2026-03-06T16:04:38","modified_gmt":"2026-03-06T21:04:38","slug":"contact-the-gross-law-firm-by-april-6-2026-deadline-to-join-class-action-against-ultragenyx-pharmaceutical-inc-rare","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/contact-the-gross-law-firm-by-april-6-2026-deadline-to-join-class-action-against-ultragenyx-pharmaceutical-inc-rare\/","title":{"rendered":"Contact The Gross Law Firm by April 6, 2026 Deadline to Join Class Action Against Ultragenyx Pharmaceutical Inc.(RARE)"},"content":{"rendered":"<div class=\"mw_release\">\n<p>NEW YORK, March  06, 2026  (GLOBE NEWSWIRE) &#8212; The Gross Law Firm issues the following notice to shareholders of\u00a0<strong>Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE).<\/strong><\/p>\n<p>Shareholders who purchased shares of RARE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.<\/p>\n<p align=\"center\">CONTACT US HERE:<\/p>\n<p align=\"center\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2ePBc1eAAiwwHhbTwQMUDr66GXIa5btFEZomOgi1dNEDRKscats2uUWqwQzIngz5wM3OSjTU8-9mdLO8BK8zCg8V0DfwrAuLt2pK0rSXjAPh_mqCrwelIot89c6L1e3Eoz6kqOKmxUr8gtAHKLbOwJhUbMpQxZjhgZj4-0DcZ9gbX5fOOY6pgg88qSC_07fwhAbPpJBVCaQpMTzDsSJJ2xPF8bEiWcVqQtwhnoJY-abofAenIPa3RZlgzstAxEQElDr3EjCl19BnfeZWegB6PhDLTGjHFJvIv4Zl_SkRIoUWFvpUozUy-yf4KxVLv2pO0jtjaDHccs-pa5l2KkqVMA==\" rel=\"nofollow\" target=\"_blank\">https:\/\/securitiesclasslaw.com\/securities\/ultragenyx-pharmaceutical-inc-loss-submission-form-2\/?id=184109&amp;from=3<\/a>\n      <\/p>\n<p>\n        <strong>CLASS PERIOD: <\/strong>August 3, 2023 to December 26, 2025<\/p>\n<p>\n        <strong>ALLEGATIONS: <\/strong>According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and\/or concealing material adverse facts concerning the true state of setrusumab\u2019s potential and the true risk inherent in the study protocols put forth; notably, that, while setrusumab does increase material bone density, this increase does not correlate to a decrease in annualized fracture rates or otherwise the Phase III Orbit and Cosmic studies were much less likely to be able to demonstrate such a link than management claimed. On December 29, 2025, Ultragenyx announced that both its Phase III Orbit and Cosmic Studies had not \u201cachieved statistical significance against the primary endpoints of reduction in annualized clinical fracture rate compared to placebo or bisphosphonates, respectively.\u201d The Company attributed the study failure to a \u201clow fracture rate in the placebo group\u201d of Orbit and a trend that fell shy of statistical significance in Cosmic. Following this news, the price of Ultragenyx\u2019s common stock declined dramatically. From a closing market price of $34.19 per share on December 26, 2025, Ultragenyx\u2019s stock price fell to $19.72 per share on December 29, 2025, a decline of about 42.32% in the span of just a single day.<\/p>\n<p>\n        <strong>DEADLINE: April 6, 2026<\/strong> Shareholders should not delay in registering for this class action. Register your information here: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2ePBc1eAAiwwHhbTwQMUDr66GXIa5btFEZomOgi1dNEDRKscats2uUWqwQzIngz5wM3OSjTU8-9mdLO8BK8zCg8V0DfwrAuLt2pK0rSXjAPh_mqCrwelIot89c6L1e3Eoz6kqOKmxUr8gtAHKLbOwJhUbMpQxZjhgZj4-0DcZ9i_t73WyhviQlmDKW6Fs-U-FH9V0sLcXu9FckUKNW-P0XRXeb2jYSMI3f_i2CqGFdhzfTsjQj_Tv0iQeBBFmlFjEs9zpd52L0UZGarqGD6XdMhzqmbpd5FgH-r5mnlqLLcB6or9YiPSHjC5lXIEXGoy5BaDDGFbBGACxd6FRonNdg==\" rel=\"nofollow\" target=\"_blank\">https:\/\/securitiesclasslaw.com\/securities\/ultragenyx-pharmaceutical-inc-loss-submission-form-2\/?id=184109&amp;from=3<\/a><\/p>\n<p>\n        <strong>NEXT STEPS FOR SHAREHOLDERS: <\/strong>Once you register as a shareholder who purchased shares of RARE during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is April 6, 2026. There is no cost or obligation to you to participate in this case.<\/p>\n<p>\n        <strong>WHY GROSS LAW FIRM? <\/strong>The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and\/or misleading statements or the omission of material information by a company lead to artificial inflation of the company&#8217;s stock. Attorney advertising. Prior results do not guarantee similar outcomes.<\/p>\n<p>\n        <strong>CONTACT:<\/strong><br \/>\n        <br \/>The Gross Law Firm<br \/>15 West 38th Street, 12th floor<br \/>New York, NY, 10018<br \/>Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=81DQD4TVvzxGDLL3AoTW55dDOcNMD5ozMEjT5mxh420Qx9d7LwlGjQL9lzRUx-5CCV-alR4_12LK71f3qg5-ngFJW3IaD5YJjntkyFfyxMmOenm28Ck3-nMffLlHMB0w\" rel=\"nofollow\" target=\"_blank\">dg@securitiesclasslaw.com<\/a><br \/>Phone: (646) 453-8903<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NjgyOSM3NDcwNDQxIzIyNTg5MTc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NmY5YjExZWUtNjg5YS00MGUyLTgzYzktNjIzNzg1MmMwNTIxLTEyNzA0NjctMjAyNi0wMy0wNi1lbg==\/tiny\/The-Gross-Law-Firm.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) &#8212; The Gross Law Firm issues the following notice to shareholders of\u00a0Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). Shareholders who purchased shares of RARE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https:\/\/securitiesclasslaw.com\/securities\/ultragenyx-pharmaceutical-inc-loss-submission-form-2\/?id=184109&amp;from=3 CLASS PERIOD: August 3, 2023 to December 26, 2025 ALLEGATIONS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and\/or concealing material adverse facts concerning the true state of setrusumab\u2019s potential and the true risk inherent in the study protocols put forth; notably, that, while setrusumab &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/contact-the-gross-law-firm-by-april-6-2026-deadline-to-join-class-action-against-ultragenyx-pharmaceutical-inc-rare\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Contact The Gross Law Firm by April 6, 2026 Deadline to Join Class Action Against Ultragenyx Pharmaceutical Inc.(RARE)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-942704","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Contact The Gross Law Firm by April 6, 2026 Deadline to Join Class Action Against Ultragenyx Pharmaceutical Inc.(RARE) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/contact-the-gross-law-firm-by-april-6-2026-deadline-to-join-class-action-against-ultragenyx-pharmaceutical-inc-rare\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Contact The Gross Law Firm by April 6, 2026 Deadline to Join Class Action Against Ultragenyx Pharmaceutical Inc.(RARE) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) &#8212; The Gross Law Firm issues the following notice to shareholders of\u00a0Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). Shareholders who purchased shares of RARE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https:\/\/securitiesclasslaw.com\/securities\/ultragenyx-pharmaceutical-inc-loss-submission-form-2\/?id=184109&amp;from=3 CLASS PERIOD: August 3, 2023 to December 26, 2025 ALLEGATIONS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and\/or concealing material adverse facts concerning the true state of setrusumab\u2019s potential and the true risk inherent in the study protocols put forth; notably, that, while setrusumab &hellip; Continue reading &quot;Contact The Gross Law Firm by April 6, 2026 Deadline to Join Class Action Against Ultragenyx Pharmaceutical Inc.(RARE)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/contact-the-gross-law-firm-by-april-6-2026-deadline-to-join-class-action-against-ultragenyx-pharmaceutical-inc-rare\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-06T21:04:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NjgyOSM3NDcwNDQxIzIyNTg5MTc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/contact-the-gross-law-firm-by-april-6-2026-deadline-to-join-class-action-against-ultragenyx-pharmaceutical-inc-rare\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/contact-the-gross-law-firm-by-april-6-2026-deadline-to-join-class-action-against-ultragenyx-pharmaceutical-inc-rare\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Contact The Gross Law Firm by April 6, 2026 Deadline to Join Class Action Against Ultragenyx Pharmaceutical Inc.(RARE)\",\"datePublished\":\"2026-03-06T21:04:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/contact-the-gross-law-firm-by-april-6-2026-deadline-to-join-class-action-against-ultragenyx-pharmaceutical-inc-rare\\\/\"},\"wordCount\":500,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/contact-the-gross-law-firm-by-april-6-2026-deadline-to-join-class-action-against-ultragenyx-pharmaceutical-inc-rare\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NjgyOSM3NDcwNDQxIzIyNTg5MTc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/contact-the-gross-law-firm-by-april-6-2026-deadline-to-join-class-action-against-ultragenyx-pharmaceutical-inc-rare\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/contact-the-gross-law-firm-by-april-6-2026-deadline-to-join-class-action-against-ultragenyx-pharmaceutical-inc-rare\\\/\",\"name\":\"Contact The Gross Law Firm by April 6, 2026 Deadline to Join Class Action Against Ultragenyx Pharmaceutical Inc.(RARE) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/contact-the-gross-law-firm-by-april-6-2026-deadline-to-join-class-action-against-ultragenyx-pharmaceutical-inc-rare\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/contact-the-gross-law-firm-by-april-6-2026-deadline-to-join-class-action-against-ultragenyx-pharmaceutical-inc-rare\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NjgyOSM3NDcwNDQxIzIyNTg5MTc=\",\"datePublished\":\"2026-03-06T21:04:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/contact-the-gross-law-firm-by-april-6-2026-deadline-to-join-class-action-against-ultragenyx-pharmaceutical-inc-rare\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/contact-the-gross-law-firm-by-april-6-2026-deadline-to-join-class-action-against-ultragenyx-pharmaceutical-inc-rare\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/contact-the-gross-law-firm-by-april-6-2026-deadline-to-join-class-action-against-ultragenyx-pharmaceutical-inc-rare\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NjgyOSM3NDcwNDQxIzIyNTg5MTc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NjgyOSM3NDcwNDQxIzIyNTg5MTc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/contact-the-gross-law-firm-by-april-6-2026-deadline-to-join-class-action-against-ultragenyx-pharmaceutical-inc-rare\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Contact The Gross Law Firm by April 6, 2026 Deadline to Join Class Action Against Ultragenyx Pharmaceutical Inc.(RARE)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Contact The Gross Law Firm by April 6, 2026 Deadline to Join Class Action Against Ultragenyx Pharmaceutical Inc.(RARE) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/contact-the-gross-law-firm-by-april-6-2026-deadline-to-join-class-action-against-ultragenyx-pharmaceutical-inc-rare\/","og_locale":"en_US","og_type":"article","og_title":"Contact The Gross Law Firm by April 6, 2026 Deadline to Join Class Action Against Ultragenyx Pharmaceutical Inc.(RARE) - Market Newsdesk","og_description":"NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) &#8212; The Gross Law Firm issues the following notice to shareholders of\u00a0Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). Shareholders who purchased shares of RARE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https:\/\/securitiesclasslaw.com\/securities\/ultragenyx-pharmaceutical-inc-loss-submission-form-2\/?id=184109&amp;from=3 CLASS PERIOD: August 3, 2023 to December 26, 2025 ALLEGATIONS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and\/or concealing material adverse facts concerning the true state of setrusumab\u2019s potential and the true risk inherent in the study protocols put forth; notably, that, while setrusumab &hellip; Continue reading \"Contact The Gross Law Firm by April 6, 2026 Deadline to Join Class Action Against Ultragenyx Pharmaceutical Inc.(RARE)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/contact-the-gross-law-firm-by-april-6-2026-deadline-to-join-class-action-against-ultragenyx-pharmaceutical-inc-rare\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-06T21:04:38+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NjgyOSM3NDcwNDQxIzIyNTg5MTc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/contact-the-gross-law-firm-by-april-6-2026-deadline-to-join-class-action-against-ultragenyx-pharmaceutical-inc-rare\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/contact-the-gross-law-firm-by-april-6-2026-deadline-to-join-class-action-against-ultragenyx-pharmaceutical-inc-rare\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Contact The Gross Law Firm by April 6, 2026 Deadline to Join Class Action Against Ultragenyx Pharmaceutical Inc.(RARE)","datePublished":"2026-03-06T21:04:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/contact-the-gross-law-firm-by-april-6-2026-deadline-to-join-class-action-against-ultragenyx-pharmaceutical-inc-rare\/"},"wordCount":500,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/contact-the-gross-law-firm-by-april-6-2026-deadline-to-join-class-action-against-ultragenyx-pharmaceutical-inc-rare\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NjgyOSM3NDcwNDQxIzIyNTg5MTc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/contact-the-gross-law-firm-by-april-6-2026-deadline-to-join-class-action-against-ultragenyx-pharmaceutical-inc-rare\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/contact-the-gross-law-firm-by-april-6-2026-deadline-to-join-class-action-against-ultragenyx-pharmaceutical-inc-rare\/","name":"Contact The Gross Law Firm by April 6, 2026 Deadline to Join Class Action Against Ultragenyx Pharmaceutical Inc.(RARE) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/contact-the-gross-law-firm-by-april-6-2026-deadline-to-join-class-action-against-ultragenyx-pharmaceutical-inc-rare\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/contact-the-gross-law-firm-by-april-6-2026-deadline-to-join-class-action-against-ultragenyx-pharmaceutical-inc-rare\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NjgyOSM3NDcwNDQxIzIyNTg5MTc=","datePublished":"2026-03-06T21:04:38+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/contact-the-gross-law-firm-by-april-6-2026-deadline-to-join-class-action-against-ultragenyx-pharmaceutical-inc-rare\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/contact-the-gross-law-firm-by-april-6-2026-deadline-to-join-class-action-against-ultragenyx-pharmaceutical-inc-rare\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/contact-the-gross-law-firm-by-april-6-2026-deadline-to-join-class-action-against-ultragenyx-pharmaceutical-inc-rare\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NjgyOSM3NDcwNDQxIzIyNTg5MTc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NjgyOSM3NDcwNDQxIzIyNTg5MTc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/contact-the-gross-law-firm-by-april-6-2026-deadline-to-join-class-action-against-ultragenyx-pharmaceutical-inc-rare\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Contact The Gross Law Firm by April 6, 2026 Deadline to Join Class Action Against Ultragenyx Pharmaceutical Inc.(RARE)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/942704","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=942704"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/942704\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=942704"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=942704"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=942704"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}